Novel Imaging Markers in SPMS (NCT05357833) | Clinical Trial Compass
CompletedEarly Phase 1
Novel Imaging Markers in SPMS
United States11 participantsStarted 2022-06-01
Plain-language summary
This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinning neurologic worsening in progressive MS. As such, in the short term this project proposes to investigate USPIO uptake in SPMS lesions as a promising in vivo imaging biomarker for chronic-active lesions, as distinguished from chronic-inactive lesions.
Who can participate
Age range35 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
. Acute or chronic kidney disease with eGFR \<30 ml/min/1.73m2
✕. Pacemaker or other MRI contraindications per American College of Radiology guidelines
✕. Intravenous iron sensitivity
✕. Serum ferritin and transferrin saturation above age-adjusted upper limit of normal (if serum ferritin is above normal, but transferrin saturation is normal, the subject is NOT excluded)